The British Pharmacological Society (BPS) is pleased to announce that the British Journal of Pharmacology (BJP) will accept open access articles, subject to payment of a publication fee.
The journal is moving to a mixed revenue model of subscription charges and publication fees. The open access option will be available to all authors submitting on or after 1 April 2006. For the remainder of 2006, the publication fee will be $2,500, €1850 or £1250 + VAT (where applicable). Articles published with a publication fee will be clearly identified in the online and print editions of the journal with a ‘BJP Open’ logo (BJPOpen).
Editors will be blind to the author’s choice, avoiding any possibility of a conflict of interest during through peer review and acceptance. Authors paying the publication fee will be entitled to self-archive the published version immediately on publication, in the repositories of their choice, and in any format. Other articles will continue to be published under Nature Publishing Group’s (NPG) exclusive License-to-Publish, where NPG’s usual self-archiving policy will apply.
Print subscription prices will be unaffected. This change follows the introduction of ‘Online Open’ on the British Journal of Clinical Pharmacology, published by BPS and Blackwell Publishing. BPS is committed to providing authors with all the relevant publishing options in this period of technology change, while protecting the financial foundations of its publications which support its charitable activities for the advancement of pharmacology.
BJP is published by NPG on behalf of BPS.
Posted by
Peter Suber at 3/17/2006 08:02:00 AM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
I recommend the OA tracking project (OATP) as the best way to stay on top of new OA developments. You can read the OATP feed on a blog-like web page or subscribe to it by RSS, email, or Twitter. You can also help build the feed by tagging new developments you encounter.
